Explore key insights from Acumen Pharmaceuticals' Q1 2024 earnings, focusing on their innovative Alzheimer's treatments and financial outlook.
Despite a net loss, MRVI showcases strategic expansions and robust partnerships, setting the stage for future growth.
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.